Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corvex, Inc.MOVE · Entity 5811 | Director | March 13, 2026 | March 17, 2026 |
| Tvardi Therapeutics, Inc.TVRD · Entity 7579 | Director | April 15, 2025 | May 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corvex, Inc.
Report date March 13, 2026 · Filed March 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,960 |
Reported balance
After 2026-03-13 transaction · row 1
1 source rowRow 1 · 2026-03-13 · Exercise / conversion · Acquired 10,000 · Balance 15,960 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.25 · Expires 2026-06-30 | Direct | 0 |
Reported balance
After 2026-03-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-13 · Exercise / conversion · Disposed 10,000 · Balance 0 F1: This option award was granted contingent upon shareholder approval of an amendment to the Omnibus Incentive Plan that increases the number of shares of Common Stock authorized for issuance under the Plan (the "Plan Amendment"). The option became exerciseable upon shareholder approval of the Plan Amendment on December 16, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This option award was granted contingent upon shareholder approval of an amendment to the Omnibus Incentive Plan that increases the number of shares of Common Stock authorized for issuance under the Plan (the "Plan Amendment"). The option became exerciseable upon shareholder approval of the Plan Amendment on December 16, 2025.
Tvardi Therapeutics, Inc.
Report date April 15, 2025 · Filed May 02, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectPalkon Holdings, LLC | 176,030 |
Reported balance
After 2025-04-15 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-04-15 · Grant · Acquired 176,030 · Balance 176,030 F1: The initial Form 4 inadvertently listed an incorrect transaction code. F2: Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the "Merger"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc. F3: Received in exchange for 1,312,508 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement. F4: The Reporting Person is a Managing Manager of the Palkon Holdings LLC and Palkon TT Holdings LLC (the "Palkon entities"). The Reporting Person may be deemed to share the power to direct the disposition and vote of the shares held by the Palkon entities, but disclaims beneficial ownership, except to any pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectPalkon TT Holdings, LLC | 263,164 |
Reported balance
After 2025-04-15 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2025-04-15 · Grant · Acquired 263,164 · Balance 263,164 F1: The initial Form 4 inadvertently listed an incorrect transaction code. F2: Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the "Merger"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc. F5: Received in exchange for 1,962,199 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement. F4: The Reporting Person is a Managing Manager of the Palkon Holdings LLC and Palkon TT Holdings LLC (the "Palkon entities"). The Reporting Person may be deemed to share the power to direct the disposition and vote of the shares held by the Palkon entities, but disclaims beneficial ownership, except to any pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The initial Form 4 inadvertently listed an incorrect transaction code.
F2: Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the "Merger"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc.
F3: Received in exchange for 1,312,508 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement.
F4: The Reporting Person is a Managing Manager of the Palkon Holdings LLC and Palkon TT Holdings LLC (the "Palkon entities"). The Reporting Person may be deemed to share the power to direct the disposition and vote of the shares held by the Palkon entities, but disclaims beneficial ownership, except to any pecuniary interests therein.
F5: Received in exchange for 1,962,199 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2026 Filed Mar 17, 2026 18:01 UTC | Corvex, Inc. MOVE · Entity 5811 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001193125-26-111336 · ownership.xml · derivative · entry 2 Wirk Shaheen · CIK 0002050227 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option award was granted contingent upon shareholder approval of an amendment to the Omnibus Incentive Plan that increases the number of shares of Common Stock authorized for issuance under the Plan (the "Plan Amendment"). The option became exerciseable upon shareholder approval of the Plan Amendment on December 16, 2025. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 18:01 UTC | Corvex, Inc. MOVE · Entity 5811 | Exercise / conversionCommon Stock | 10,000 | $1.25 | $12,500.00 |
DisclosureSEC source: 0001193125-26-111336 · ownership.xml · nonDerivative · entry 1 Wirk Shaheen · CIK 0002050227 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2026 Filed Jan 12, 2026 17:54 UTC | Corvex, Inc. MOVE · Entity 5811 | GrantCommon Stock | 2,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010715 · ownership.xml · nonDerivative · entry 2 Wirk Shaheen · CIK 0002050227 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,860 F2 · shares: The reported transaction involved the reporting person's receipt of a grant of 2,980 RSUs under the Company's Omnibus Incentive Plan for the period January 1, 2026 to June 30, 2026. Read SEC document |
| January 09, 2026 Filed Jan 12, 2026 17:54 UTC | Corvex, Inc. MOVE · Entity 5811 | GrantCommon Stock | 2,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010715 · ownership.xml · nonDerivative · entry 1 Wirk Shaheen · CIK 0002050227 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,980 F1 · shares: The reported transaction involved the reporting person's receipt of a grant of 2,980 restricted stock units ("RSUs") under the Company's Omnibus Incentive Plan in lieu of cash directors' fees for the period January 1, 2026 to June 30, 2026. Read SEC document |
| November 03, 2025 Filed Nov 10, 2025 17:55 UTC | Corvex, Inc. MOVE · Entity 5811 | GrantStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001193125-25-274674 · ownership.xml · derivative · entry 2 Wirk Shaheen · CIK 0002050227 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2025-12-31 F2 · derivative.exercise_date: This option award was granted contingent upon shareholder approval of an amendment to the Omnibus Incentive Plan that increases the number of shares of Common Stock authorized for issuance under the Plan (the "Plan Amendment"). The option will become exerciseable upon shareholder approval of the Plan Amendment. Read SEC document |
| November 03, 2025 Filed Nov 10, 2025 17:55 UTC | Corvex, Inc. MOVE · Entity 5811 | Disposition to issuerCommon Stock | 6,841 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-274674 · ownership.xml · nonDerivative · entry 1 Wirk Shaheen · CIK 0002050227 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: The reported transaction involved the reporting person's forfeiture of previously awarded restricted stock units ("RSUs") under the Company's Omnibus Inctive Plan (the "Omnibus Incentive Plan") in lieu of directors' fees in exchange for the grant of stock options. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 09:24 UTC | Corvex, Inc. MOVE · Entity 5811 | GrantCommon Stock | 20,685 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-232768 · ownership.xml · nonDerivative · entry 1 Wirk Shaheen · CIK 0002050227 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,412 F1 · shares: The reported transaction involved the reporting person's receipt of a grant of 20,685 restricted stock units ("RSUs") under the Company's Omnibus Incentive Plan in lieu of directors' fees for the period October 1, 2025 to December 31, 2025. The total reported in Column 5 consists solely of RSUs. Read SEC document |
| July 03, 2025 Filed Jul 3, 2025 16:30 UTC | Corvex, Inc. MOVE · Entity 5811 | GrantCommon Stock | 18,657 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-093920 · ownership.xml · nonDerivative · entry 1 Wirk Shaheen · CIK 0002050227 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,727 F1 · shares: The reported transaction involved the reporting person's receipt of a grant of 18,657 restricted stock units ("RSUs") under the Company's Omnibus Incentive Plan in lieu of directors' fees for the period July 1, 2025 to September 30, 2025. The total reported in Column 5 consists solely of RSUs. Read SEC document |
| May 09, 2025 Filed May 13, 2025 16:30 UTC | Corvex, Inc. MOVE · Entity 5811 | GrantCommon Stock | 29,070 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-070430 · ownership.xml · nonDerivative · entry 1 Wirk Shaheen · CIK 0002050227 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,070 F1 · shares: The reported transaction involved the reporting person's receipt of a grant of 29,070 restricted stock units ("RSUs") under the Company's Omnibus Incentive Plan in lieu of directors' fees for the period October 1, 2024 to June 30, 2025. Read SEC document |
| April 17, 2025 Filed Apr 21, 2025 17:15 UTC | Tvardi Therapeutics, Inc. TVRD · Entity 7579 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $17.04 | $0.00 |
DisclosureSEC source: 0001415889-25-011111 · form4-04212025_050411.xml · derivative · entry 1 Wirk Shaheen · CIK 0002050227 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2035-04-16 F1 · derivative.exercise_date: The shares subject to the option shall vest and become exercisable over three years in 12 equal quarterly installments commencing on July 17, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 18:50 UTC | Tvardi Therapeutics, Inc. TVRD · Entity 7579 | GrantStock Option (right to buy) · Derivative | 2,011 | Not disclosed Strike: $0.68 | Not disclosed |
DisclosureSEC source: 0001415889-25-010980 · form4-04172025_060409.xml · derivative · entry 4 Wirk Shaheen · CIK 0002050227 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,011 Underlying: Common Stock · 2,011 shares Expires 2031-01-29 F7 · price: Received in exchange for a stock option to acquire 15,000 shares of common stock of Legacy Tvardi with the exercise price of $0.09 per share pursuant the Merger Agreement. F8 · price: Under the terms of the Merger, with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F6 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 18:50 UTC | Tvardi Therapeutics, Inc. TVRD · Entity 7579 | OtherCommon Stock | 263,164 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-010980 · form4-04172025_060409.xml · nonDerivative · entry 3 Wirk Shaheen · CIK 0002050227 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Palkon TT Holdings, LLC Disclosed balance after: 263,164 F2 · kind: Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the "Merger"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc. F5 · kind: Received in exchange for 1,962,199 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement. F2 · price: Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the "Merger"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc. F5 · price: Received in exchange for 1,962,199 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement. F4 · ownership.nature: The Reporting Person is a Managing Manager of the Palkon Holdings LLC and Palkon TT Holdings LLC (the "Palkon entities"). The Reporting Person may be deemed to share the power to direct the disposition and vote of the shares held by the Palkon entities, but disclaims beneficial ownership, except to any pecuniary interests therein. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 18:50 UTC | Tvardi Therapeutics, Inc. TVRD · Entity 7579 | OtherCommon Stock | 176,030 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-010980 · form4-04172025_060409.xml · nonDerivative · entry 2 Wirk Shaheen · CIK 0002050227 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Palkon Holdings, LLC Disclosed balance after: 176,030 F2 · kind: Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the "Merger"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc. F3 · kind: Received in exchange for 1,312,508 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement. F2 · price: Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the "Merger"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc. F3 · price: Received in exchange for 1,312,508 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement. F4 · ownership.nature: The Reporting Person is a Managing Manager of the Palkon Holdings LLC and Palkon TT Holdings LLC (the "Palkon entities"). The Reporting Person may be deemed to share the power to direct the disposition and vote of the shares held by the Palkon entities, but disclaims beneficial ownership, except to any pecuniary interests therein. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 18:50 UTC | Tvardi Therapeutics, Inc. TVRD · Entity 7579 | GrantCommon Stock | 4,191 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-010980 · form4-04172025_060409.xml · nonDerivative · entry 1 Wirk Shaheen · CIK 0002050227 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,191 F1 · price: Received in exchange for 31,252 shares of Series B Preferred Stock of Tvardi Therapeutics, Inc. ("Legacy Tvardi") pursuant to Agreement and Plan of Merger and Reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub") and Legacy Tvardi, as amended (the "Merger Agreement"). F2 · price: Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the "Merger"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc. Read SEC document |
| April 15, 2025 Filed May 2, 2025 18:12 UTC Amendment | Tvardi Therapeutics, Inc. TVRD · Entity 7579 | GrantCommon Stock | 263,164 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-011857 · form4a-05022025_100517.xml · nonDerivative · entry 2 Wirk Shaheen · CIK 0002050227 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Palkon TT Holdings, LLC Disclosed balance after: 263,164 F1 · kind: The initial Form 4 inadvertently listed an incorrect transaction code. F2 · price: Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the "Merger"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc. F5 · price: Received in exchange for 1,962,199 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement. F4 · ownership.nature: The Reporting Person is a Managing Manager of the Palkon Holdings LLC and Palkon TT Holdings LLC (the "Palkon entities"). The Reporting Person may be deemed to share the power to direct the disposition and vote of the shares held by the Palkon entities, but disclaims beneficial ownership, except to any pecuniary interests therein. Read SEC document |
| April 15, 2025 Filed May 2, 2025 18:12 UTC Amendment | Tvardi Therapeutics, Inc. TVRD · Entity 7579 | GrantCommon Stock | 176,030 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-011857 · form4a-05022025_100517.xml · nonDerivative · entry 1 Wirk Shaheen · CIK 0002050227 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Palkon Holdings, LLC Disclosed balance after: 176,030 F1 · kind: The initial Form 4 inadvertently listed an incorrect transaction code. F2 · price: Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the "Merger"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc. F3 · price: Received in exchange for 1,312,508 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement. F4 · ownership.nature: The Reporting Person is a Managing Manager of the Palkon Holdings LLC and Palkon TT Holdings LLC (the "Palkon entities"). The Reporting Person may be deemed to share the power to direct the disposition and vote of the shares held by the Palkon entities, but disclaims beneficial ownership, except to any pecuniary interests therein. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 16:29 UTC | Corvex, Inc. MOVE · Entity 5811 | GrantStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0000950170-25-002172 · ownership.xml · derivative · entry 2 Wirk Shaheen · CIK 0002050227 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-01-02 F3 · derivative.exercise_date: The option vests in full on the one year anniversary of the grant date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 16:29 UTC | Corvex, Inc. MOVE · Entity 5811 | GrantStock Options (Right to Buy) · Derivative | 13,300 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0000950170-25-002172 · ownership.xml · derivative · entry 1 Wirk Shaheen · CIK 0002050227 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,300 Underlying: Common Stock · 13,300 shares Expires 2035-01-02 F1 · shares: Represents a stock option award granted on 1/2/2025 pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: The options will vest and become exercisable in forty-eight equal monthly installments beginning on the date that is one month following the grant date; provided that immediately prior to, and contingent upon, a change in control, the options will become fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.